All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC1325 | Human anti-Vimentin T cell receptor (FDR W1.1), pCDTCR1 | Human | FDR W1.1 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1326 | Human anti-Vimentin T cell receptor (FDR W1.2), pCDTCR1 | Human | FDR W1.2 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1327 | Human anti-Vimentin T cell receptor (FDR W1.3), pCDTCR1 | Human | FDR W1.3 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1328 | Human anti-Vimentin T cell receptor (FDR W1.4), pCDTCR1 | Human | FDR W1.4 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1329 | Human anti-Vimentin T cell receptor (FDR W1.5), pCDTCR1 | Human | FDR W1.5 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1330 | Human anti-Vimentin T cell receptor (RA W1.1), pCDTCR1 | Human | RA W1.1 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1331 | Human anti-Vimentin T cell receptor (RA W1.2), pCDTCR1 | Human | RA W1.2 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1332 | Human anti-Vimentin T cell receptor (RA W1.3), pCDTCR1 | Human | RA W1.3 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1333 | Human anti-Vimentin T cell receptor (RA W1.4), pCDTCR1 | Human | RA W1.4 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1334 | Human anti-Vimentin T cell receptor (RA W1:1), pCDTCR1 | Human | RA W1:1 | Human | GVYATRSSAVRLR + CITR(R6) | HLA-DRB1*04:01 | Lentiviral vector | |
TCR-YC1335 | Human anti-Vimentin T cell receptor (RA W1:2), pCDTCR1 | Human | RA W1:2 | Human | GVYATRSSAVRLR | HLA-DRB1*04:01 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION